NEW YORK, Aug. 26, 2013 /PRNewswire/ -- Bernstein Liebhard
LLP is investigating whether the Board of Directors of Onyx
Pharmaceuticals, Inc. ("Onyx" or the "Company") (NASDAQ: ONXX)
breached its fiduciary duty to its shareholders in agreeing to sell
Onyx to Amgen.
(Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO
)
Under the terms of the agreement, Onyx shareholders will receive
$125.00 in cash for each share they
own. The investigation is focused on the potential unfairness
of the price to Onyx shareholders and the process by which the Onyx
Board of Directors considered and approved the transaction.
If you are interested in discussing your rights as an Onyx
stockholder, with no obligation or cost to you, please contact
Joseph Seidman at:
(877) 779-1414
or
seidman@bernlieb.com.
Bernstein Liebhard LLP has pursued hundreds of securities,
consumer and shareholder rights cases and recovered over
$3 billion for its clients. It
has been named to The National Law Journal's "Plaintiffs'
Hot List" in each of the last ten years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
www.bernlieb.com
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The
law firm responsible for this advertisement is Bernstein Liebhard
LLP, 10 East 40th Street, New York, New
York 10016, (212) 779-1414. The lawyer responsible for
this advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not
guarantee or predict a similar outcome with respect to any future
matter.
SOURCE Bernstein Liebhard LLP